
Advanced Merkel cell carcinoma - Pipeline Insight, 2024
Description
Advanced Merkel cell carcinoma - Pipeline Insight, 2024
DelveInsight’s, “Advanced Merkel cell carcinoma - Pipeline Insight, 2024,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Advanced Merkel cell carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Advanced Merkel cell carcinoma: Overview
Advanced Merkel cell carcinoma (MCC) is a very aggressive, rare neuroendocrine tumor of the skin with a high frequency of locoregional recurrence and metastasis, and a high mortality rate. Surgical resection, sentinel lymph node biopsy, and radiotherapy represent the gold standard of treatment in patients with localized disease, while chemotherapy has a significant role in the treatment of advanced disease. However, no definitive evidence on the survival impact of radiotherapy in the advanced stages has been provided to date, and response to chemotherapy remains brief in the majority of cases, indicating an urgent need for alternative approaches. Biological and genome sequencing studies have implicated multiple molecular pathways in MCC, thus leading to the development of new agents that target angiogenic factors, anti-apoptosis molecules, poly-ADP ribose polymerase, intracellular signal proteins such as the PI3K/AKT/mTOR pathway, and peptide receptors such as somatostatin receptors.
""Advanced Merkel cell carcinoma - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Merkel cell carcinoma pipeline landscape is provided which includes the disease overview and Advanced Merkel cell carcinoma treatment guidelines. The assessment part of the report embraces, in depth Advanced Merkel cell carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Merkel cell carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Merkel cell carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Merkel cell carcinoma.
This segment of the Advanced Merkel cell carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Advanced Merkel cell carcinoma Emerging Drugs
- Tidutamab: Xencor, Inc.
- Cabozantinib: Exelixis
Further product details are provided in the report……..
Advanced Merkel cell carcinoma: Therapeutic Assessment
This segment of the report provides insights about the different Advanced Merkel cell carcinoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Advanced Merkel cell carcinoma
Phases
DelveInsight’s report covers around 20+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Advanced Merkel cell carcinoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Merkel cell carcinoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Merkel cell carcinoma drugs.
Advanced Merkel cell carcinoma Report Insights
- Advanced Merkel cell carcinoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Advanced Merkel cell carcinoma drugs?
- How many Advanced Merkel cell carcinoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Merkel cell carcinoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Advanced Merkel cell carcinoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Advanced Merkel cell carcinoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- 4SC AG
- Xencor, Inc.
- Incyte Corporation
- Millennium Pharmaceuticals, Inc.
- Exelixis
- Bristol-Myers Squibb
- bluebird bio
- Affini-T Therapeutics
- ImaginAb, Inc.
- BioInvent International AB
- Ocellaris Pharma, Inc.
- Sotio a.s.
- Morphogenesis, Inc.
- Checkpoint Therapeutics, Inc.
- Tidutamab
- Domatinostat
- MLN0128
- Cabozantinib
- Nivolumab
- FH-MCVA2TCR
- SO-C101
- CK-301
- IFx-Hu2.0
- 89Zr-Df-Crefmirlimab
- BT-001
- OC-001 "
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Advanced Merkel cell carcinoma: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Advanced Merkel cell carcinoma – DelveInsight’s Analytical Perspective
- Mid Stage Products (Phase II)
- Comparative Analysis
- Cabozantinib: Exelixis
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- IFx-Hu2.0: Morphogenesis
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Advanced Merkel cell carcinoma Key Companies
- Advanced Merkel cell carcinoma Key Products
- Advanced Merkel cell carcinoma- Unmet Needs
- Advanced Merkel cell carcinoma- Market Drivers and Barriers
- Advanced Merkel cell carcinoma- Future Perspectives and Conclusion
- Advanced Merkel cell carcinoma Analyst Views
- Advanced Merkel cell carcinoma Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.